# Abridge AI

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/abridge-ai

- Industry: Healthcare IT
- Headquarters: Philadelphia, US
- Website: www.abridge.com
- Total disclosed funding: $765M
- Latest round: Series E (Jun 12, 2025)
- Investors on record: 26

## About

Based in the US, Abridge AI, Inc. specializes in generative AI technology that transforms clinical conversations into actionable, billable notes, enhancing the efficiency of healthcare providers and improving patient outcomes. Founded in 2018, Abridge AI, Inc. operates from its headquarters in Pittsburgh, US, focusing on innovative healthcare documentation solutions. The founders Shiv Rao (CEO), Florian Metze, and Sandeep Konam have collectively contributed to the company's growth. In June 2026, Abridge AI, Inc. raised an undisclosed amount of venture funding from Lilly. Abridge specializes in advanced generative AI technology tailored for clinical conversations, transforming patient-clinician interactions into contextually aware, clinically useful, and billable AI-generated notes. The Abridge Contextual Reasoning Engine streamlines clinical documentation by capturing conversation essences in real-time, significantly reducing clinicians’ cognitive load and enhancing patient care. Their solutions serve a diverse clientele, including healthcare leaders such as Johns Hopkins, Kaiser Permanente, Duke Health, and the Mayo Clinic, improving clinician efficiency and patient outcomes across various settings. Abridge's products integrate seamlessly into existing workflows and support multilingual environments within the United States market, allowing healthcare professionals to focus more on patient care instead of administrative tasks. Abridge generates revenue through enterprise-grade AI solutions structured as subscription-based models, enabling healthcare organizations to access its innovative clinical documentation technology. Major healthcare providers partner with Abridge to utilize its services, aimed at increasing documentation compliance and closing revenue cycle gaps. The pricing model reflects service value with tailored plans for different healthcare systems. Abridge's flagship offerings enhance operational performance and facilitate accurate capture of billable services in real-time, fostering a collaborative environment with healthcare organizations. The company will use the June 2026 funding to support evidence-based care and research and expand its integration of payer and life sciences workflows.

## Funding rounds

- Series E, Jun 12, 2025, $316M — Khosla Ventures, Andreessen Horowitz
- Series D, Nov 14, 2024, $250M — Institutional Venture Partners, Lightspeed Venture Partners, Redpoint Ventures, California Healthcare Foundation, Spark Capital, Bessemer Venture Partners, SV Angel, CapitalG, Nventures, CVS Health Ventures, K. Ventures
- Series C, Feb 22, 2024, $141M — Institutional Venture Partners, Lightspeed Venture Partners, Redpoint Ventures, Union Square Ventures, Spark Capital, Bessemer Venture Partners, Kaiser Permanente Ventures, Mass General Brigham Ventures, Wittington Ventures, CVS Health Ventures, NVentures
- Series B, Oct 26, 2023, $30M — Spark Capital, Bessemer Venture Partners, Kaiser Permanente Ventures, Mayo Clinic, American College of Cardiology Foundation, UC Ventures, LifePoint Health, Scan Health Plan, CVS Health Ventures
- Series A, Aug 11, 2022, $13M — Union Square Ventures, Bessemer Venture Partners, Pillar, UPMC Enterprises, Wittington Ventures, Whistler Capital Partners
- Series A, Oct 6, 2020, $10M — Union Square Ventures, Bessemer Venture Partners, Pillar, UPMC Enterprises, KdT Ventures
- Seed, Feb 15, 2019, $5M — Pillar, KdT Ventures

## Investors

- Pillar (https://capitalatlas.ai/funds/pillar) — Seed, Series A
- KdT Ventures (https://capitalatlas.ai/funds/kdt-ventures) — Seed, Series A
- Union Square Ventures (https://capitalatlas.ai/funds/union-square-ventures) — Series A, Series C
- Bessemer Venture Partners (https://capitalatlas.ai/funds/bessemer-venture-partners) — Series A, Series B, Series C, Series D
- UPMC Enterprises (https://capitalatlas.ai/funds/upmc-enterprises) — Series A
- Wittington Ventures (https://capitalatlas.ai/funds/wittington-ventures) — Series A, Series C
- Whistler Capital Partners (https://capitalatlas.ai/funds/whistler-capital-partners) — Series A
- Spark Capital — Series B, Series C, Series D
- Kaiser Permanente Ventures (https://capitalatlas.ai/funds/kaiser-permanente-ventures) — Series B, Series C
- Mayo Clinic — Series B
- American College of Cardiology Foundation — Series B
- UC Ventures (https://capitalatlas.ai/funds/uc-ventures) — Series B
- LifePoint Health — Series B
- Scan Health Plan — Series B
- CVS Health Ventures (https://capitalatlas.ai/funds/cvs-health-ventures) — Series B, Series C, Series D
- Institutional Venture Partners (https://capitalatlas.ai/funds/institutional-venture-partners) — Series C, Series D
- Lightspeed Venture Partners (https://capitalatlas.ai/funds/lightspeed-venture-partners) — Series C, Series D
- Redpoint Ventures (https://capitalatlas.ai/funds/redpoint-ventures) — Series C, Series D
- Mass General Brigham Ventures (https://capitalatlas.ai/funds/mass-general-brigham-ventures) — Series C
- NVentures — Series C, Series D
- California Healthcare Foundation — Series D
- SV Angel (https://capitalatlas.ai/funds/sv-angel) — Series D
- CapitalG (https://capitalatlas.ai/funds/capitalg) — Series D
- K. Ventures (https://capitalatlas.ai/funds/k-ventures) — Series D
- Khosla Ventures (https://capitalatlas.ai/funds/khosla-ventures) — Series E
- Andreessen Horowitz (https://capitalatlas.ai/funds/andreessen-horowitz) — Series E